What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
HOLX's Genius digital cytology system and global rollout position its Cytology unit for long-term growth despite near-term headwinds.
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength
HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.
Hologic's Diagnostics Arm Set for Long-Term Upside: What's Behind It?
HOLX's Diagnostics arm eyes long-term growth with new assays, platform expansion and oncology test adoption despite headwinds.
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings?
HOLX rises post earnings beat, fueled by Diagnostics strength and Surgical growth. However, macro headwinds persist.
Why Hologic (HOLX) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Interpreting Hologic (HOLX) International Revenue Trends
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down
HOLX posts better-than-expected Q3 results, but margin contraction and regional headwinds pressure investor sentiment.
Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript
Hologic, Inc. (NASDAQ:HOLX ) Q3 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Essex D. Mitchell - Chief Operating Officer Karleen M.
Compared to Estimates, Hologic (HOLX) Q3 Earnings: A Look at Key Metrics
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hologic (HOLX) Q3 Earnings and Revenues Beat Estimates
Hologic (HOLX) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.06 per share a year ago.
